Swansea Bay University Health Board is the local health board of NHS Wales for Swansea and Neath Port Talbot, in the south-west of Wales. Established as Abertawe Bro Morgannwg University Health Board in 2009, it was renamed and had its boundaries altered on 1 April 2019.

During the past decade, Swansea Bay University Health Board conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 3 clinical trials were completed, i.e. on average, 17.6% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 3 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Swansea Bay University Health Board" #1 sponsor was "Abbott Medical Devices" with 5 trials, followed by "Swansea Bay University Health Board" with 3 trials sponsored, "ADC Therapeutics S.A." with 1 trials sponsored, "Bangor University" with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Swansea Bay University Health Board" #1 collaborator was "National Institute for Health Research, United Kingdom" with 2 trials as a collaborator, "Swansea University" with 2 trials as a collaborator, "University of Manchester" with 2 trials as a collaborator, "AdventHealth" with 1 trials as a collaborator and "Alder Hey Children's NHS Foundation Trust" with 1 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Swansea Bay University Health Board" are "Aortic Valve Stenosis" (2 trials), "Symptomatic Severe Aortic Stenosis" (2 trials), "Acute Coronary Syndrome" (1 trials), "Allograft" (1 trials) and "Aortic Insufficiency" (1 trials). Many other conditions were trialed in "Swansea Bay University Health Board" in a lesser frequency.

Most popular intervention types in "Swansea Bay University Health Board" are "Device" (7 trials), "Drug" (5 trials), "Other" (5 trials), "Procedure" (5 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Cisplatin" (2 trials), "Paclitaxel" (2 trials), "A computerized tomography (CT) coronary angiogram" (1 trials), "Adjuvant therapies" (1 trials) and "Blood tests for inflammation and oxidative stress markers" (1 trials). Other intervention names were less common.

The vast majority of trials in "Swansea Bay University Health Board" are 17 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Swansea Bay University Health Board". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Swansea Bay University Health Board, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Swansea Bay University Health Board, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 9 trials that are defined as “Not Applicable".